<DOC>
	<DOC>NCT00169065</DOC>
	<brief_summary>This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.</brief_summary>
	<brief_title>Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia</brief_title>
	<detailed_description>This is a two-year open-label, randomized trial of the comparative effectiveness of clozapine versus olanzapine in patients with treatment refractory schizophrenia. The objective is to determine whether in a naturalistic setting olanzapine is a logical treatment choice (before using the more toxic clozapine) for some treatment refractory patients.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Age 2060 years; Diagnosis of treatment refractory schizophrenia or schizoaffective disorder; BPRS score &gt; 21 (06) scale; Either two 68 week trials of typical neuroleptics given at a dosage of 600 mg/day of CPZ or its equivalent or one 68 week trial of an atypical antipsychotic at a reasonable dose (i.e. risperidone 46 mg/day); The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent; Clinically appropriate for clozapine or olanzapine Current substance abuse; Suicide or homicide risk; Pregnancy or lactation; History of seizures or blood dyscrasias</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Clozapine</keyword>
	<keyword>olanzapine</keyword>
</DOC>